Laboratorios Farmaceuticos Rovi (ES:ROVI) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Laboratorios Farmacéuticos ROVI has successfully passed all proposed resolutions during its Ordinary General Shareholders’ Meeting, including the approval of annual accounts, management reports, a dividend payout, and the re-election of board members and auditors for the upcoming year. Shareholders endorsed a dividend distribution equivalent to 35% of the 2023 consolidated profit, and confirmed KPMG Auditores, S.L. as the company’s auditors for 2024. The company will also implement a Long-Term Incentive Plan and a share capital reduction by amortizing its own shares.
For further insights into ES:ROVI stock, check out TipRanks’ Stock Analysis page.